4//SEC Filing
DAVIS JAMES H 4
Accession 0001225208-12-016951
CIK 0000901219other
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 11:53 AM ET
Size
21.4 KB
Accession
0001225208-12-016951
Insider Transaction Report
Form 4
DAVIS JAMES H
Exec. VP, Gen Counsel & Sec.
Transactions
- Disposition from Tender
Common Stock
2012-07-30$14.25/sh−165,032$2,351,706→ 0 total - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−118,827$1,693,285→ 0 totalExercise: $10.62Exp: 2017-03-10→ Common Stock (118,827 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−119,473$1,702,490→ 0 totalExercise: $0.52Exp: 2019-03-10→ Common Stock (119,473 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−89,828$1,280,049→ 0 totalExercise: $12.56Exp: 2015-01-17→ Common Stock (89,828 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−87,002$1,239,779→ 0 totalExercise: $10.89Exp: 2016-03-14→ Common Stock (87,002 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−138,031$1,966,942→ 0 totalExercise: $4.92Exp: 2018-03-10→ Common Stock (138,031 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−108,000$1,539,000→ 0 totalExercise: $8.23Exp: 2022-03-10→ Common Stock (108,000 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−91,923$1,309,903→ 0 totalExercise: $12.38Exp: 2013-12-10→ Common Stock (91,923 underlying)
Footnotes (7)
- [F1]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $151,809.32, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F2]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $431,342.01, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F3]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $1,287,829.23, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F4]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $1,640,364.29, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F5]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $650,160.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F6]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $292,326.72, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F7]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $171,896.01, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
Documents
Issuer
HUMAN GENOME SCIENCES INC
CIK 0000901219
Entity typeother
Related Parties
1- filerCIK 0001191231
Filing Metadata
- Form type
- 4
- Filed
- Jul 31, 8:00 PM ET
- Accepted
- Aug 1, 11:53 AM ET
- Size
- 21.4 KB